Live EventMarch 21, 2024 from 6:30 pm to 8:30 pm CDT
Major Depressive Disorder affects more than 260 million people worldwide. The reported prevalence of depression in patients with Chronic Kidney Disease (CKD) ranges from 20-65%. This presentation provides an overview… Read More
Major Depressive Disorder affects more than 260 million people worldwide1. The reported prevalence of depression in patients with Chronic Kidney Disease (CKD) ranges from 20-65%2. This presentation provides an overview… Read More
This presentation discusses the challenges patients with end-stage kidney disease face and explores the barriers and benefits of living kidney donation. Read More
Major depressive disorder (MDD) affects more than 260 million people worldwide. The reported prevalence of depression in patients with chronic kidney disease (CKD) ranges from 20-65%. This presentation provides an… Read More
This presentation discusses the challenges patients with end-stage kidney disease face and explores the barriers and benefits of living kidney donation. Read More
This presentation reviews and counters common perceived barriers to utilizing peritoneal dialysis in various populations. Read More
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.